CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $21.11, for a total transaction of $52,775.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Debanjan Ray also recently made the following trade(s):

  • On Friday, December 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $20.58, for a total transaction of $51,450.00.
  • On Wednesday, November 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00.

CytomX Therapeutics, Inc. (CTMX) traded up $0.63 during mid-day trading on Wednesday, reaching $22.39. 240,932 shares of the company’s stock were exchanged, compared to its average volume of 266,100. CytomX Therapeutics, Inc. has a 1 year low of $10.64 and a 1 year high of $24.67. The company has a market capitalization of $859.97 and a PE ratio of -14.26.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its holdings in shares of CytomX Therapeutics by 1.3% during the second quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock worth $343,000 after buying an additional 292 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of CytomX Therapeutics by 28.6% during the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after buying an additional 1,434 shares in the last quarter. Nationwide Fund Advisors lifted its holdings in shares of CytomX Therapeutics by 39.4% during the second quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after buying an additional 4,622 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of CytomX Therapeutics by 18.6% during the third quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after buying an additional 5,800 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in shares of CytomX Therapeutics during the third quarter worth $107,000. 63.13% of the stock is owned by institutional investors.

Several equities analysts recently weighed in on CTMX shares. Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research note on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price for the company. Bank of America raised their target price on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Nomura raised their target price on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. CytomX Therapeutics currently has a consensus rating of “Hold” and an average target price of $31.88.

TRADEMARK VIOLATION WARNING: “Debanjan Ray Sells 2,500 Shares of CytomX Therapeutics, Inc. (CTMX) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/03/debanjan-ray-sells-2500-shares-of-cytomx-therapeutics-inc-ctmx-stock-2.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.